- Shaikh A. and Shih J. “Chemotherapy-induced cardiotoxicity.” Curr Heart Fail Rep. (2012); 9(2):117-27.
- Raj S., Franco V.and Lipshultz S. “Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment”. Curr Treat Options Cardiovasc Med (2014); 16:315.
- Shaikh A., McGuiness M. and Shih J. “Cardiovascular toxicity of newer chemotherapeutic agents the heart of the matter.” Oncology (Williston Park). (2014); 28(6):493- 496.
- Blum J., Flynn P. and Yothers G. “Anthracyclines in Early Breast Cancer”: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol (2017); 35:2647.
- Monsuez J., Charniot J., Vignat N. et al. “Cardiacside-effects of cancer chemotherapy.” Int J Cardiol. (2010); 144:3-15.
- Cardinale D., Colombo A. and Lamantia G. “Anthracycline-induced cardiomyopathy.” Clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. (2010); 55(3):213-20.
- Claus, P., Omar, A., Pedrizzetti G. et al. “Tissue tracking technology for assessing cardiac mechanics” Principles, normal values, and clinical applications. JACC Imaging (2015), 8, 1444–1460.
- Thavendiranathan P., Poulin F. and Lim K. “Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy” a systematic review. J Am Coll Cardiol (2014); 63:2751.
- Lang R., Badano L. and Mor-Avi V. “Recommendations for cardiac chamber quantification by echocardiography in adults:” an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr (2015); 28:1.
- Zamorano J., Lancellotti P. and Rodriguez Muñoz. “2016 ESC Position Paper on cancer treatments and cardiovascular toxicity” developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J (2016); 37:2768.
- Curigliano G., Cardinale D. and Suter T. “Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy” ESMO Clinical Practice Guidelines. Ann Oncol (2012); 23 Suppl 7:vii155–vii166.
- Ky B., Putt M. and Sawaya H. “Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab”. J Am Coll Cardiol (2014); 63:809.
- De Lemos J., Drazner M., Omland T. et al. “Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population.” JAMA (2010); 304:2503–2512.
- Yu K., Xiaoping X., Leilei C., et al “Two‐dimensional speckle tracking echocardiography combined with high‐sensitive cardiac troponin I in early detection and prediction of cardiotoxicity during epirubicine‐based chemotherapy European Journal of Heart Failure” (2013) European Society of Cardiology.
- Motoki H., Koyama, J., Nakazawa, H. et al. “Torsion analysis in the early detection of anthracycline-mediated cardiomyopathy.” Eur. Heart J. Cardiovasc. Imaging, (2012) 13(1): 95–103.
- Tsai, H., Gjesdal, O., Wethal, T., et al. “Left ventricular function assessed by two-dimensional speckle tracking echocardiography in long-term survivors of Hodgkin's lymphoma treated by mediastinal radiotherapy with or without anthracycline therapy”. Am. J. Cardiol. (2011) 107(3): 472–477.
- Mornoş, C., and Petrescu, L. “Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist”. Canadian Journal of Physiology and Pharmacology, (2012) 91(8), 601–607.
- Khakoo, A., Liu, P., Force, T., et al. “Cardiotoxicity due to cancer therapy”. Tex. Heart Inst. J. (2011) 38(3): 253–256.
- Yeh, E., and Bickford, C. “Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management”. J. Am. Coll. Cardiol. (2011) 53(24): 2231–2247
- Abdel-Qadir H, Amir E and Thavendiranathan P. “Prevention, detection, and management of chemotherapy-related cardiac dysfunction”. Can J Cardiol. (2016); 32(7):891–899.
- Arciniegas Calle M, Sandhu N, Xia H, et al. “Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.” BMC Cancer. (2018); 18(1):1037.
- Kitayama, H., Kondo, T., Sugiyama, J., et al. “High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients. Breast Cancer”, (2017) 24(6), 774–782.
- Christenson E, James T, Agrawal V, et al. “Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.” Clin Biochem. (2015); 48(4–5):223–235.
- Gripp E, Oliveira G, Feijó L, et al. “Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients during Anthracycline and/or Trastuzumab Treatment”. Arq Bras Cardiol. (2018); 110(2):140–150.
- Boyd A., Stoodley, P., Richards, D., and et al. “Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study”. PLOS ONE, (2017) 12(4), e0175544.
- Patel N., Chyu C., Satou G. “Left atrial function in children and young adult cancer survivors treated with anthracyclines. Echocardiography” (2018).
- Li V., Liu A., So E., “Two- and three-dimensional myocardial strain imaging in the interrogation of sex differences in cardiac mechanics of long-term survivors of childhood cancers”. The International Journal of Cardiovascular Imaging (2018).
- Zordoky B, Radin M, Heller L, et al “the interplay between genetic background and sexual dimorphism of doxorubicin- induced Cardiotoxicity”. Cardiooncology (2016) 2:4
- Zhang J, Knapton A, Lipshultz SE, et al. “Sex-related differences in mast cell activity and doxorubicin toxicity: a study in spontaneously hypertensive rats”. Toxicol Pathol (2016) 42:361–375.
- Moulin M, Piquereau J, Mateo P, et al. “Sexual dimorphism of doxorubicin mediated cardiotoxicity potential role of energy metabolism remodeling”. Circ Heart Fail (2015) 8:98–108.
- Ho E, Brown A, Barrett P, et al. “Subclinical anthracycline- and trastuzumab- induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: A speckle tracking echocardiographic study”. Heart. (2010); 96: 701±707.
- Santoro C., Arpino G., Esposito R., et al. “2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility.” European Heart Journal - Cardiovascular Imaging, (2017) 18(8), 930–936.
- Rhea I, Uppuluri S, Sawada S, et al. “Incremental prognostic value of echocardiographic strain and its association with mortality in cancer patients”. J Am Soc Echocardiogr. (2015); 28(6):667–673.
- Blaes A, Rehman A, Vock D, et al. “Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy”. Vasc Health Risk Manag. (2015); 11:591–594.
- Advani P., Hoyne J., Moreno-Aspita, A. et al. “High-Sensitivity Troponin T and NT-proBNP Kinetics in Breast Cancer Chemotherapy.” Chemotherapy, (2017) 62(6), 334–338.
- Farsalinos K, Daraban A, Ünlü S, et al. “Head to-head comparison of global longitudinal strain measurements among nine different vendors: the EACVI/ASE Inter-Vendor Comparison study”. J Am Soc Echocardiogr (2015); 28:1171–81.
- Hu H, Zhang X, Zhang W, et al. “Detection of Subclinical Anthracyclines' Cardiotoxicity in Children with Solid Tumor.” Chin Med J (Engl). (2018) ; 131(12):1450–1456.
- Jones M., O’Gorman P., Kelly C., et al. “High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury.” Annals of Clinical Biochemistry, (2017) 54(1), 149–157.
- Sawaya H, Sebag I, Plana J, et al. “Early detection and prediction of cardiotoxicity in chemotherapy-treated patients”. Am J Cardiol (2011); 107:1375-80.
- Ky B, Putt M, Sawaya H, et al. “Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab”. J Am Coll Cardiol (2014); 63:809–816.
- Yoon G., Telli M., Kao D., et al. “Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?” J Am Coll Cardiol (2010); 56:1644-50.
|